Menu
Back to User profile » Professor Yunpeng Yang
Papers published by Professor Yunpeng Yang:
A retrospective analysis of the clinicopathological and molecular characteristics of pulmonary blastoma
Zhao YY, Liu L, Zhou T, Zhou NN, Yang YP, Hou X, Li Y, Zhao HY, Huang Y, Zhang L
OncoTargets and Therapy 2016, 9:6915-6920
Published Date: 8 November 2016
Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma
Zhang XK, Qin T, Zeng YD, Zhao YY, Hou X, Fang WF, Hong SD, Zhou T, Hu ZH, Yang YP, Ma YX, Xue C, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2015, 8:1219-1227
Published Date: 26 May 2015
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L
Drug Design, Development and Therapy 2014, 8:1827-1837
Published Date: 10 October 2014
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
Hong SD, Fang WF, Liang WH, Yan Y, Zhou T, Qin T, Wu X, Ma YX, Zhao YY, Yang YP, Hu ZH, Xue C, Hou X, Chen Y, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2014, 7:1851-1867
Published Date: 7 October 2014
Randomized double-blind trial of prophylactic topical Evozac® Calming Skin Spray for gefitinib-associated acne-like eruption
Wang Y, Yang Y, Xu J, Yu J, Liu X, Gao R, Zhang L
OncoTargets and Therapy 2014, 7:1261-1266
Published Date: 10 July 2014
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
Wu X, Liang WH, Hou X, Lin Z, Zhao HY, Huang Y, Fang WF, Zhao YY, Wu JX, Yang YP, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Zhou T, Qin T, Zhang L
OncoTargets and Therapy 2013, 6:1481-1491
Published Date: 21 October 2013